ViAqua Therapeutics

Company Overview

Snapshot

Founded in September 2014 by Shai Ufaz and Shai Einbinder, ViAqua Therapeutics operates with 11–50 employees. The company has raised a total of $16.05 million across 5 funding rounds from 11 investors. In September 2023, the company secured funding from investors including S2G Investments.

Business overview

ViAqua Therapeutics develops an orally administered treatment platform aimed at improving health management and preventing viral epidemics in aquaculture. The company's core technology utilizes a proprietary RNAi formulation delivered via coated particles in feed, which triggers the immune system to prevent viral infections in shellfish and fish. Its initial product targets shrimp, a significant segment of the international fish products trade, operating within the Agriculture & Food Technologies sector and serving markets in Asia, South America, and Australia.

Strategic signal

In September 2023, ViAqua Therapeutics successfully raised $8.25 million in a funding round. This capital infusion, with participation from investors such as S2G Investments and I-Lab Angels, signals continued investor confidence in. The funding supports the company's ongoing development and commercialization efforts, reinforcing its trajectory as a key innovator in sustainable farming and disease management.

Company Intelligence Q&A

What is ViAqua Therapeutics' primary focus?

ViAqua Therapeutics focuses on developing an orally administered treatment platform to improve health management and prevent viral epidemics in aquaculture, particularly targeting shrimp initially.

When was ViAqua Therapeutics founded and by whom?

ViAqua Therapeutics was founded in September 2014 by Shai Ufaz and Shai Einbinder.

How much capital has ViAqua Therapeutics raised to date?

ViAqua Therapeutics has raised a total of $16.05 million across 5 funding rounds.

Which investors participated in ViAqua Therapeutics' September 2023 funding round?

In September 2023, ViAqua Therapeutics secured funding from investors including.

What is the core technology behind ViAqua Therapeutics' products?

ViAqua Therapeutics' platform utilizes a proprietary RNAi formulation delivered via feed, designed to trigger the immune system and prevent viral infections in shellfish and fish.